Lynn Kirkpatrick

2.0k total citations
23 papers, 1.6k citations indexed

About

Lynn Kirkpatrick is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Lynn Kirkpatrick has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Lynn Kirkpatrick's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Cancer, Hypoxia, and Metabolism (4 papers) and ATP Synthase and ATPases Research (3 papers). Lynn Kirkpatrick is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Cancer, Hypoxia, and Metabolism (4 papers) and ATP Synthase and ATPases Research (3 papers). Lynn Kirkpatrick collaborates with scholars based in United States, Belgium and South Korea. Lynn Kirkpatrick's co-authors include Garth Powis, Ryan Williams, Gillian Paine-Murrieta, Sarah J. Welsh, Nathan T. Ihle, Peter Wipf, Robert J. Halter, Amanda F. Baker, Robert T. Abraham and Margareta Berggren and has published in prestigious journals such as Journal of Clinical Oncology, Nature Biotechnology and Cancer Research.

In The Last Decade

Lynn Kirkpatrick

22 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lynn Kirkpatrick United States	15	991	679	295	179	116	23	1.6k
Jung-Sik Kim United States	26	1.5k 1.5×	406 0.6×	596 2.0×	313 1.7×	90 0.8×	45	2.2k
Hans‐Willi Krell Germany	17	479 0.5×	541 0.8×	356 1.2×	58 0.3×	149 1.3×	22	1.2k
Margaret Willard United States	10	1.0k 1.0×	719 1.1×	438 1.5×	172 1.0×	122 1.1×	12	1.7k
Roberta Lugano Sweden	14	1.1k 1.1×	532 0.8×	558 1.9×	225 1.3×	58 0.5×	22	2.0k
Jean-Marc Schlaeppi Switzerland	18	1.1k 1.1×	377 0.6×	561 1.9×	257 1.4×	70 0.6×	25	1.9k
Christine M. Chresta United Kingdom	21	1.5k 1.5×	335 0.5×	827 2.8×	207 1.2×	107 0.9×	33	2.1k
Florian J. Sulzmaier United States	16	959 1.0×	312 0.5×	492 1.7×	126 0.7×	106 0.9×	25	1.7k
José L. Orgaz Spain	20	938 0.9×	320 0.5×	544 1.8×	117 0.7×	27 0.2×	26	1.6k
Maurizio Orlandini Italy	26	1.3k 1.3×	217 0.3×	493 1.7×	94 0.5×	94 0.8×	66	1.9k
Andrew Chantry United Kingdom	24	1.4k 1.4×	326 0.5×	415 1.4×	131 0.7×	36 0.3×	43	1.9k

Countries citing papers authored by Lynn Kirkpatrick

Since Specialization

Citations

This map shows the geographic impact of Lynn Kirkpatrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Kirkpatrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Kirkpatrick more than expected).

Fields of papers citing papers by Lynn Kirkpatrick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn Kirkpatrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Kirkpatrick. The network helps show where Lynn Kirkpatrick may publish in the future.

Co-authorship network of co-authors of Lynn Kirkpatrick

This figure shows the co-authorship network connecting the top 25 collaborators of Lynn Kirkpatrick. A scholar is included among the top collaborators of Lynn Kirkpatrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn Kirkpatrick. Lynn Kirkpatrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Powis, Garth, et al.. (2023). Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease. Biomedicine & Pharmacotherapy. 165. 115024–115024. 24 indexed citations

Jeung, Hei‐Cheul, Alexander E. Aleshin, Ricardo G. Correa, et al.. (2021). PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. Experimental Cell Research. 409(2). 112930–112930. 4 indexed citations

Ihle, Nathan T., Geoffrey Grandjean, Michael J. Scott, et al.. (2019). An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. Cancer Research. 79(12). 3100–3111. 23 indexed citations

Kirkpatrick, Lynn, et al.. (2019). Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication. Regulatory Toxicology and Pharmacology. 108. 104433–104433.

Lemos, Robert, et al.. (2017). Abstract 3015: Selective inhibition of mutant KRAS cell and tumor growth by PHT-7.3, an inhibitor of the KRas signaling nanocluster protein Cnk1. Cancer Research. 77(13_Supplement). 3015–3015. 1 indexed citations

Nathan, Paul, Victoria M.L. Cohen, Sarah E. Coupland, et al.. (2015). Uveal Melanoma UK National Guidelines. European Journal of Cancer. 51(16). 2404–2412. 89 indexed citations

Kirkpatrick, Lynn. (2015). Incubators for innovators. Nature Biotechnology. 33(2). 129–132. 4 indexed citations

Ramanathan, Ramesh K., Joe Stephenson, Glen J. Weiss, et al.. (2011). A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Investigational New Drugs. 30(4). 1591–1596. 32 indexed citations

Kiriakova, Galina M., et al.. (2011). Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation.. Molecular Cancer Therapeutics. 10(11_Supplement). A199–A199. 2 indexed citations

10.

Kirkpatrick, Lynn, et al.. (2011). Abstract C137: Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA.. Molecular Cancer Therapeutics. 10(11_Supplement). C137–C137. 1 indexed citations

11.

Jacoby, Jörg J., Baruch Erez, Ryan Williams, et al.. (2010). Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. Journal of Thoracic Oncology. 5(7). 940–949. 67 indexed citations

12.

Ramanathan, Ramesh K., James L. Abbruzzese, Tomislav Dragovich, et al.. (2010). A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemotherapy and Pharmacology. 67(3). 503–509. 104 indexed citations

13.

Williams, Ryan, et al.. (2006). The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemotherapy and Pharmacology. 58(4). 444–450. 25 indexed citations

14.

Jordan, Bénédicte F., Matthew Runquist, Natarajan Raghunand, et al.. (2005). Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1α Using PX-478. Neoplasia. 7(5). 475–485. 107 indexed citations

15.

Wipf, Peter, Robert J. Halter, Margareta Berggren, et al.. (2004). Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Organic & Biomolecular Chemistry. 2(13). 1911–1911. 69 indexed citations

16.

Meuillet, Emmanuelle J., Nathan T. Ihle, Amanda F. Baker, et al.. (2004). In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 14(10). 513–527. 46 indexed citations

17.

Powis, Garth & Lynn Kirkpatrick. (2004). Hypoxia inducible factor-1α as a cancer drug target. Molecular Cancer Therapeutics. 3(5). 647–654. 264 indexed citations

18.

Welsh, Sarah J., Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, & Garth Powis. (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.. PubMed. 3(3). 233–44. 243 indexed citations

19.

Welsh, Sarah J., Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, & Garth Powis. (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Molecular Cancer Therapeutics. 3(3). 233–244. 192 indexed citations

20.

Houtz, John C., et al.. (1979). Relationship among measures of evaluation ability (problem solving), creative thinking, and intelligence. Contemporary Educational Psychology. 4(1). 47–54. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact